HEALTH PROFESSIONAL · SOURCE READING

Combination immunotherapy and targeted therapy

Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Locally Advanced or Metastatic Primary Liver Cancer / Treatment Options for Locally Advanced or Metastatic Primary Liver Cancer / First-line systemic therapy

The combination of atezolizumab (an anti–PD-L1 inhibitor) and bevacizumab (a VEGF inhibitor) has produced improved OS compared with sorafenib. The FDA approved this combination for patients with advanced HCC and Child-Pugh class A liver function. Additional combination therapies are being evaluated.

Continue within this section

Atezolizumab and bevacizumab →Atezolizumab and cabozantinib →

Preserved source evidence · Not medical advice